Business Wire

Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022

Share

Galderma will present a range of new clinical data and analyses across its portfolio during nine poster sessions and two symposia at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.

“At Galderma, we are committed to advancing dermatology for every skin story. The extensive series of oral and poster presentations with new data from across our portfolio demonstrates our drive for innovation across the industry. We will also be hosting two symposia with leading physicians, reinforcing our partnership with the aesthetics community as we present work completed with them to deliver holistic individualized treatments (HITs) for patients and the science and clinical experience behind our latest innovation Alluzience, the first ready-to-use neuromodulator”

Flemming Ørnskov, M.D., MPH

Chief Executive Officer

Galderma

Latest efficacy, safety & satisfaction data for neuromodulator portfolio

Alluzience

Two oral presentations and a poster will center on data for Alluzience, the first ready to use liquid (abobotulinumtoxinA), approved in June 2021 in Europe. Pooled data from two phase III studies (NCT02353871 and NCT02493946) demonstrated that Alluzience effectively improved frown line severity, with rapid onset of effect and up to 6 months improvement after a single treatment.1-3 Improvements in the severity of frown lines, satisfaction and psychological well-being were maintained over repeated treatment cycles.1 Additional post-hoc analyzes will be presented that confirm that the median time to return to baseline rating was nearly six months.3

The clinical data that will be presented are listed below:

Poster title

Authors

Number

Poster

presentation

Ready-to-use liquid abobotulinumtoxinA: An overview of available phase III clinical data for moderate-to-severe glabellar line treatment

Benjamin Ascher, et al.

#113846

Oral

Presentation

16:45 CET

June 4

Ready-to-use liquid abobotulinumtoxinA for moderate-to-severe glabellar lines: Pooling of two double-blind, randomized, controlled phase III studies

Inna Prygova, et al.

#114879

Oral

Presentation

16:30 CET

June 4

Liquid abobotulinumtoxinA for glabellar line treatment: Post hoc analysis of duration of effect and subject satisfaction phase III study data

Berthold Rzany, et al.

#114895

Delegates at IMCAS can also attend Galderma’s symposium, Alluzience: the first liquid neuromodulator – from theory to practice. During the session, an expert panel will take attendees on a journey through the science of the first ready-to-use neuromodulator and their clinical experience of the breakthrough treatment. The symposium is taking place on Saturday 4, 13:30 to 15:00 CET.

Dysport (also marketed as Azzalure® in the EU)

Clinical experience with Dysport (abobotulinumtoxinA) spans over three decades* and it has a well-established safety profile across multiple aesthetic indications including both frown lines and crow’s feet.4–14

Researchers will present three posters demonstrating that Dysport is efficacious and well tolerated, with subjects reporting natural results and high rates of satisfaction. A dose escalation study evaluated subject satisfaction using abobotulinumtoxinA doses up to 125U and demonstrated it was efficacious and well-tolerated across all doses from 50U to 125U with high satisfaction and improvement maintained for up to 9 months.15 Data was analyzed from three studies (NCT03736928, Phase 2; NCT03960957, Phase 3; NCT03687736, Phase 4) in which all subjects were treated with on-label 50 units. Subjects reported median onset of effect after two days in all three trials and high rates of subject satisfaction up to six months after injection in phase III and nine months in phase II trials.16 A post-hoc analysis of clinical trial NCT03687736 also found that while all age groups were satisfied with and experienced psychological benefits from treatment, millennials, known for their high expectations appeared to be particularly happy with two treatments a year of abobotulinumtoxinA.17

The clinical data that will be presented are listed below:

Poster title

Authors

Number

Poster

presentation

Assessment of subject satisfaction after glabellar line treatment with escalating doses of abobotulinumtoxinA in a randomized, double-blind study

Steven Dayan, et al..

#114887

Poster

presentation

Subject satisfaction and duration of effect of on-label 50U abobotulinumtoxinA treatment of glabellar lines - results from three individual trials

Steven Dayan, et al.

#114885

Poster

presentation

Subject satisfaction with twice-yearly treatment of glabellar lines with abobotulinumtoxinA in millennials

Inna Prygova, et al.

#114945

*Approved for therapeutic use in December 1990 and aesthetic use in April 2009

New data for Restylane range of hyaluronic acid fillers

Restylane

One of the oral presentations presented will report on phase IV data from the CHEEKY study which evaluated treatment outcome after providing investigators with a treatment guide to help choose the right treatment for their patient. The study demonstrated that all patients achieved the aim of their treatment, whether it was projection or contouring/volumization and that the results were natural-looking with high subject satisfaction.18

The clinical data that will be presented are listed below:

Poster title

Authors

Number

Oral

Presentation

16:00 CET

June 4

Effectiveness of cheek treatment after providing a treatment guide to help choose between hyaluronic acid filler HA-VOL or HA-LYF: the CHEEKY study

Andreas Nikolis, et al.

#114864

Poster presentation

Water uptake of hyaluronic acid fillers.

Åke Öhrlund

#114878

96 Week Data for Collagen Biostimulator

Sculptra

The latest long-term effectiveness and safety of Sculptra, the original and only poly-L-lactic acid (PLLA) approved by the FDA, will also be presented at IMCAS 2022. In this extension study for the correction of nasolabial folds, Sculptra, using the new constitution of 8 ml with 1 ml lidocaine, showed it to be well-tolerated and with long-lasting effectiveness until week 96.19

The clinical data that will be presented is shown below:

Oral

Presentation

16:15 CET

June 4

Extension study on safety and effectiveness of PLLA for correction of nasolabial folds after changes in reconstitution and injection procedures

Brenda LaTowsky,
set al.

#114971

Participants are also invited to attend the symposium, Restylane and Sculptra: Predictive Lessons from generations applied to facial rejuvenation, taking place on Saturday June 4, 08:30 to 10:00 CET. The symposium will see leading physicians offer their insights into how assessing people within the same family at different stages of their life can inform the design of holistic individualized treatments for patients.

For more information, the IMCAS 2022 program is available here.

About Galderma

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com

About Alluzience® (liquid botulinum toxin type A)

Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.20 Dosing and treatment intervals depend on assessment of the individual patient’s response.20 The treatment interval should be no more frequent than every three months.20 For more information, please see the Summary of Product Characteristics.20

Alluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in Europe (excluding Greece, Lithuania, Estonia, Latvia, Hungary).

About Dysport®

Dysport (abobotulinumtoxinA) is a prescription injection for temporary improvement in the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport is also marketed as Azzalure in the EU for the treatment of glabellar lines and lateral canthal lines. Dysport has more than 30 years of clinical experience Globally for therapeutic indications and 13 years for aesthetics indications, with extensive clinical evidence of safety and efficacy. It is licensed for aesthetic indications in 85 markets worldwide, Dysport is one of the world’s leading brands of aesthetic neuromodulators with over 100 million treatments delivered in the aesthetics indications to date.

Dysport is a product under license from Ipsen and is manufactured by them. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen’s botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, Europe and the Middle East, Australia, South Korea, Canada, Brazil, Argentina and certain other countries. Ipsen continues to promote Dysport within certain therapeutic indications in countries around the world. For more information on Ipsen, visit www.ipsen.com.

About Galderma’s Restylane® portfolio

RESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 25 years of achievement and over 50 million treatments worldwide. NASHA™ and OBT™ technologies make RESTYLANE the world’s most diverse range of fillers to deliver truly individualized results.21,22

The RESTYLANE® portfolio of products includes RESTYLANE®, RESTYLANE® LYFTTM, RESTYLANE® KYSSETM, RESTYLANE® VOLYMETM, RESTYLANE® DEFYNETM, RESTYLANE® REFYNETM, RESTYLANE® EYELIGHTTM and RESTYLANE® SKINBOOSTERS VITALTM.

About Sculptra®

SCULPTRA works to stimulate the skin’s own collagen production23 and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, and scars, and for signs of skin aging.24 SCULPTRA is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).24

SCULPTRA is an injectable biostimulator containing microparticles of poly-L-lactic acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months.25 SCULPTRA was first approved in 1999 in Europe and it is currently available in more than 40 countries globally.

References:

  1. Ascher B. Poster #113846 to be presented at IMCAS 2022.
  2. Picaut, P. Oral Presentation #114879 to be presented at IMCAS 2022.
  3. Rzany B. Oral Presentation #114895 to be presented at IMCAS 2022.
  4. Kane AC et al. Plast Reconstr Surg 2009;124:1619–29.
  5. Dysport Summary of Product Characteristics, Galderma, July 2018.
  6. Brandt F et al. Dermatol Surg 2009;35:1893–1901.
  7. Moy RM et al. Arch Facial Plast Surg 2009;11(2):77–83.
  8. Rubin MG et al. J Drugs Dermatol 2009;8(5):439–444.
  9. Schlessinger J et al. Dermatol Surg 2014;40(2):176–183.
  10. Maas C et al. Aesthet Surg J 2012;32(1S):8S–29S.
  11. Cohen JL and Scuderi N. Aesthet Surg J 2017;37(S1):S33–S44.
  12. Hexsel D et al. Dermatol Surg 2018;44(12):1555-1564.
  13. Rubin M et al. Aesthet Surg J 2009;29:S50–S56.
  14. Cohen JL et al. Aesthet Surg J 2009;29(Suppl 1):S43–S49.
  15. Dayan S et al.Poster #114887 to be presented at IMCAS 2022.
  16. Dayan S et al.Poster #114885 to be presented at IMCAS 2022.
  17. Prygova I et al. Poster #114945 to be presented at IMCAS 2022
  18. Nikolis A et al. Oral Presentation #114864 to be presented at IMCAS 2022.
  19. LaTowsky B et al. Oral Presentation #114971 to be presented at IMCAS 2022.
  20. Summary of Product Characteristics, 10 June 2021.
  21. Data on file (MA-33939).
  22. Öhrlund A. Poster presented at AMWC 2019.
  23. Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92.
  24. Sculptra IFU. 2018.
  25. Brown SA et al. Plast Reconstr Surg 2011;127(4):1684–92.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41

Tracy Krumme
Global Head of Investor Relations
tracy.krumme@galderma.com
+1 914 497 9073

Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Evolve Announces Next Phase of Development7.7.2022 17:00:00 CEST | Press release

Today Evolve Additive Solutions (“EAS”), a global leader in the manufacturing of capital equipment, announces organizational changes designed to accelerate technology developments within its production 3D printer for manufacturing customers. After 14 years of R&D investment, the company is retooling for commercialization with a focus on its highly reliable production platform and a strong customer return-on-investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005781/en/ Joe Allison, CEO, Evolve Additive Solutions (Photo: Business Wire) The company is pleased to announce that current board member, Joe Allison, will join the company as CEO. Founder, Steve Chillscyzn will transition into the role of CTO and remain on the Board of Directors. “This new structure will allow me to focus my energies on accelerating technical developments within our STEP technology,” said Steve Chillscyzn. “The versatility of the platform

Mary Kay Inc. Partners With Dr. Jack Gilbert to Further Study Skin’s “Microbiome” and the Impact on the Aging Process7.7.2022 16:30:00 CEST | Press release

Mary Kay Inc., one of the world’s leading skincare research companies, has announced a new partnership with Dr. Jack Gilbert, professor of pediatrics at the University of California San Diego School of Medicine and professor of microbial oceanography at UC San Diego Scripps Institution of Oceanography. Through the partnership, scientists at Mary Kay will work in conjunction with Dr. Gilbert to study one of the most important—but least understood—areas of aging and skin health: the skin Microbiome. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005167/en/ Mary Kay Inc. has announced a new partnership with Dr. Jack Gilbert, professor of pediatrics at the University of California San Diego School of Medicine and professor of microbial oceanography at UC San Diego Scripps Institution of Oceanography. Through the partnership, scientists at Mary Kay will work in conjunction with Dr. Gilbert to study one of the most important

Payroll Tech Leader Mercans Appoints Tatjana Domovits as its Group CEO7.7.2022 16:00:00 CEST | Press release

Mercans’ board has appointed Tatjana Domovits, a long-serving executive, as their Global CEO. Mercans’ board expressed confidence that “Tatjana is the best person to lead Mercans into the future, building world-class payroll technology, transforming global payroll and the employer-of-record industry, and making global employment frictionless.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005410/en/ Tatjana Domovits – Group CEO – Mercans (Photo: AETOSWire) This announcement comes on the back of a record-breaking year for Mercans in 2021 and its ambitious plans that focus on driving revenue growth across all business lines. Mercans’ disruptive global payroll technology, which delivers native payroll processing capabilities and integrations with local tax authorities across 160 countries, has proven to be a huge success in the global payroll industry. Mercans intends to reach annual revenues in excess of $100 million fr

Tigo Energy Welcomes Bill Roeschlein as Chief Financial Officer7.7.2022 16:00:00 CEST | Press release

Tigo Energy, Inc., the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, today announced that Bill Roeschlein has joined as its new Chief Financial Officer. In his new role, Mr. Roeschlein will lead the finance and legal teams at Tigo. He will focus on establishing the premier financial organization in the renewable energy industry, along with the processes and procedures that facilitate the growth of Tigo to the next stage of financial development. “Bill is exactly the type of Finance Executive that Tigo needs,” stated Zvi Alon, Chairman and CEO of Tigo. “His proven leadership as CFO at several different public companies combined with his experience in executing complex financial transactions including mergers, acquisitions, financings, and equity offerings will be invaluable as Tigo continues to evolve and grow.” Mr. Roeschlein brings a wealth of publicly-traded, pre-IPO, and international operations experience to the Tigo Executive Team. Mr. Roeschlein be

New Study shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis7.7.2022 14:07:00 CEST | Press release

Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005266/en/ (Photo: Amazentis) This study showed that treatment with Amazentis’ proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model. These findings highlight Mitopure’s benefits for joint and mitocho